Healthcare
Pathfinder Cell Therapy, Inc.(PFND)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 9, 2026
- Market Cap
- —
- Revenue Growth
- -100.0%
- EPS Growth
- +7.4%
- Dividend Yield
- 0.0%
Coverage: 242 bars · Jun 23, 2025 → Jun 9, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pathfinder Cell Therapy, Inc. (PFND) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 9, 2026). Baseline metrics include revenue growth of -100.0%, EPS growth of +7.4%, a dividend yield of 0.0%. What stands out right now is revenue -100.0%, EPS +7.4%, free cash flow +39.9% with operating margin 0.0% and ROIC 116.6%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines PFND price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-100.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
The operating picture looks softer than before
Revenue is at -100.0% and EPS is at +7.4%, with operating margin around 0.0%.
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PFND
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PFND Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PFND and SPY.
Company Overview
Pathfinder Cell Therapy, Inc.
Other OTC
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.
- Leadership
- Richard L. Franklin
- IPO Date
- Jan 3, 2000
- Employees
- 1
- Street Address
- 12 Bow Street
- Mailing
- Cambridge, MA, 02138
- Region
- Cambridge, MA, US
- Reporting Currency
- USD
- Investor Line
- 617-245-0289
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- —
- EV/EBITDA
- —
- Price/Sales
- —
- Price/Book
- —
Growth
- Revenue
- -100.0%
- EPS
- +7.4%
- Free Cash Flow
- +39.9%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- 31.8%
- ROIC
- 116.6%
Balance Sheet
- Debt/Equity
- —
- Current Ratio
- 0.01
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.